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O B J E C T I V E S This study sought to understand prognostic implications of increased baseline left
ventricular (LV) mass and geometric patterns in a high risk acute myocardial infarction.
B A C KG ROUND The LV hypertrophy and alterations in LV geometry are associated with an
increased risk of adverse cardiovascular events.
METHOD S Quantitative echocardiographic analyses were performed at baseline in 603 patients
from the VALIANT (VALsartan In Acute myocardial iNfarcTion) echocardiographic study. The left ventricular
mass index (LVMi) and relative wall thickness (RWT) were calculated. Patients were classiﬁed into 4 mutually
exclusive groups based on RWT and LVMi as follows: normal geometry (normal LVMi and normal RWT),
concentric remodeling (normal LVMi and increased RWT), eccentric hypertrophy (increased LVMi and normal
RWT), and concentric hypertrophy (increased LVMi and increased RWT). Cox proportional hazards models
were used to evaluate the relationships among LVMi, RWT, LV geometry, and clinical outcomes.
R E S U L T S Mean LVMi and RWT were 98.8  28.4 g/m2 and 0.38  0.08. The risk of death or the
composite end point of death from cardiovascular causes, reinfarction, heart failure, stroke, or
resuscitation after cardiac arrest was lowest for patients with normal geometry, and increased with
concentric remodeling (hazard ratio [HR]: 3.0; 95% conﬁdence interval [CI]: 1.9 to 4.9), eccentric
hypertrophy (HR: 3.1; 95% CI: 1.9 to 4.8), and concentric hypertrophy (HR: 5.4; 95% CI: 3.4 to 8.5), after
adjusting for baseline covariates. Also, baseline LVMi and RWT were associated with increased mortality
and nonfatal cardiovascular outcomes (HR: 1.22 per 10 g/m2 increase in LVMi; 95% CI: 1.20 to 1.30; p 
0.001) (HR: 1.60 per 0.1-U increase in RWT; 95% CI: 1.30 to 1.90; p 0.001). Increased risk associated with
RWT was independent of LVMi.
CONC L U S I O N S Increased baseline LV mass and abnormal LV geometry portend an increased risk
for morbidity and mortality following high-risk myocardial infarction. Concentric LV hypertrophy carries
the greatest risk of adverse cardiovascular events including death. Higher RWT was associated with an
increased risk of cardiovascular complications after high-risk myocardial infarction. (J Am Coll Cardiol
Img 2008;1:582–91) © 2008 by the American College of Cardiology Foundation
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583ncreased left ventricular (LV) mass and LV hyper-
trophy are independent predictors of cardiovascu-
lar morbidity and mortality irrespective of etiology
(1–3). The risk of death or nonfatal complications
s increased 2- to 4-fold in the presence of LV
ypertrophy in patients with hypertension, coronary
rtery disease, or uncomplicated myocardial infarc-
ion (MI) (1). The prevalence of LV hypertrophy is
losely associated with advancing age and severity of
ypertension, ranging from 6% in persons 30
ears of age to 43% in those69 years (4) and from
0% to 50% in populations with mild-to-severe
ypertension (1,4).
See page 592
The LV adaptation to arterial hypertension can
esult in different LV geometric responses, and
urther classification of hypertensive patients by
heir ventricular geometry may provide incremental
alue beyond ventricular mass for further cardio-
ascular risk stratification (5–9). Hypertensive pa-
ients with concentric LV hypertrophy have the
ighest incidence of cardiovascular events including
eath (9).
Despite the association of LV hypertrophy with
rognosis in patients with hypertension, uncertainty
till persists with regard to the independent prog-
ostic value of LV geometric patterns (10,11). In
ddition, the independent contribution of LV ge-
metry, relative wall thickness (RWT), and LV
ass to prognosis have not been well characterized
n a high-risk post-MI population. To explore the
rognostic value of LV mass and geometry in
igh-risk MI, we studied patients enrolled in the
chocardiographic substudy of the VALIANT
VALsartan In Acute myocardial iNfarcTion) trial.
E T H O D S
tudy design and patients. The VALIANT trial was
esigned to test the hypothesis that the angiotensin
eceptor blocker valsartan, either alone or in com-
ination with the proven angiotensin-converting
nzyme inhibitor captopril, would be superior or
ot inferior to a proven dose of captopril in reduc-
ng cardiovascular morbidity or mortality after MI
12). A total of 14,703 patients with heart failure,
V systolic dysfunction (ejection fraction [EF]
35% on echocardiography or 40% on contrast
ngiography), or both were enrolled within 12 h to
0 days after acute MI (12). The median duration
f follow-up was 24.7 months. Patients were ran- vomly assigned in a 1:1:1 ratio to treatment with
ither captopril (target dose 50 mg 3 times daily),
alsartan (target dose 160 mg twice daily), or the
ombination of valsartan and captopril (target doses
f 50 mg 3 times daily and 80 mg twice daily) (12).
linical sites participating in the main VALIANT
tudy were invited to enroll patients in the VAL-
ANT echocardiographic study, and patients en-
olled in the VALIANT trial at these sites were
ligible for inclusion in the VALIANT echocardio-
raphic study. Entry criteria were identical to those
or the main VALIANT study. Patients were in-
luded regardless of infarct location or ST-segment
haracteristics. A total of 610 patients from the
otal VALIANT population (N  14,703) were
nrolled in the echocardiographic substudy and
nderwent baseline 2-dimensional echocardiogra-
hy at a mean time of 5.0  2.5 days following the
ndex MI (13). A total of 94 clinical sites in 13
ountries participated in the VALIANT echocar-
iographic substudy. The details of patient
haracteristics have been previously de-
cribed (13) and the inclusion and exclu-
ion criteria were identical to those of the
ain VALIANT study. The demograph-
cs of the echocardiographic participants
ere similar to the overall study group (13).
chocardiographic analysis. Echocardio-
rams from videotape were digitized and
nalyses were performed on an offline
nalysis workstation in a core laboratory.
f the initial cohort, 7 patients were ex-
luded before analysis because of insuffi-
ient echocardiographic images and 603 patients
ere available at baseline for quantitative echocar-
iographic analysis.
The LV endocardial borders were manually
raced at end diastole and end systole at the mitral
nd papillary short axis level and apical 4- and
-chamber views from 3 separate cardiac cycles by a
ingle experienced observer. The LV volumes were
erived according to the modified biplane Simp-
on’s rule in the apical 4- and 2-chamber views and
ndexed to body surface area. The EF was calculated
n the standard fashion from LV end-diastolic and
systolic volume. Right ventricular (RV) function
xpressed as the RV fractional area change was
ssessed quantitatively as the percentage of change
n cavity area from end diastole to end systole. Left
trial (LA) volume was assessed by the biplane
rea-length method from apical 4- and 2-chamber
iews at end systole from the frame preceding mitral
A B B
A N D
EF e
LA
LV
LVMi
index
MI
RV
RWTalve opening. The LA volume index was calcR E V I A T I O N S
A C R O N YM S
jection fraction
left atrial
left ventricular
 left ventricular mass
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584s LA volume/body surface area (ml/m2). Mitral
ow velocity was assessed by pulsed wave Doppler
tudy from the apical 4-chambers view by position-
ng the sample volume at the tip of the mitral
eaflets.
The LV mass was calculated from LV linear
imensions using the following formula (14,15):
V mass g
 0.80 {1.04 [(septal wall thickness in diastole
LV internal diastolic diameter
 posterior wall thickness in diastole)3
 (LV internal diastolic diameter)3]} 0.6 g
The LV mass was indexed to body surface area
nd LV hypertrophy was considered present when
chocardiographically derived LV mass index
LVMi) was115 g/m2 for men and95 g/m2 for
omen (15). The RWT was calculated as 2 
posterior wall thickness in diastole) / (LV internal
iastolic diameter). Increased RWT was present
hen this ratio was 0.42 (15). The sample was
ivided into 4 mutually exclusive groups on the
asis of LV geometry: concentric hypertrophy (LV
ypertrophy and increased RWT), eccentric hyper-
rophy (LV hypertrophy and normal RWT), con-
entric remodeling (normal LVMi and increased
WT), and normal geometry (normal LVMi and
ormal RWT) (15).
tatistical analysis. Echocardiographic measure-
ents were made in triplicate by a single experi-
nced observer blinded to outcome data using
uantitative analysis software. Reproducibility was
ssessed after studies were randomly chosen and
eanalyzed with the observer blinded to the initial
esults. The coefficient of variability based on the
ntraobserver reproducibility assessment was 8.3%,
.7%, 3.0%, and 5.3% for LV volumes, LV mass,
A volume, and RV fractional area change assess-
ent, respectively, and the coefficient of variability
ased on the interobserver reproducibility assess-
ent for LV mass was 3.0%.
Continuous data were expressed as mean 
tandard deviation. Among the 4 categories of LV
eometrical patterns, categorical variables were an-
lyzed with the chi-square test. Continuous vari-
bles were analyzed with analysis of variance
Scheffe post-hoc) test.
Defined time-dependent clinical outcomes in-
luded the primary end point of all-cause mortality
nd the composite cardiovascular end point and its
ndividual components of cardiovascular death, re-
urrent MI, heart failure, stroke, and resuscitated budden death (12). Clinical outcomes were adjudi-
ated by an independent Clinical Endpoints Com-
ittee (12). To determine the independent prog-
ostic value of baseline LVMi, LV mass to end-
iastolic volume ratio, and RWT and LV geometric
atterns, we used a multivariable Cox proportional
azards model. The adjustment model included
redictors of mortality identified from the overall
ALIANT study: age (in years), primary percuta-
eous transluminal coronary angioplasty, atrial fi-
rillation complicating MI, history of diabetes,
istory of hypertension, prior MI, Killip class,
istory of congestive heart failure, new left bundle
ranch block, history of angina, LVEF, estimated
lomerular filtration rate, and a history of chronic
bstructive pulmonary disease. Both stepwise elim-
nation and backward selection were used to select
he most parsimonious set of predictive variables. In
ddition, we also included in our adjusted model
aseline measures of LV end-diastolic volume, LA
olume index, and infarct length. To assess the
ndependent prognostic value of RWT above that
f LV mass, multivariable analysis was performed
fter adjustment for LV mass as a continuous
ariable and the candidate variables listed above in a
ox proportional hazards model. Kaplan-Meier
stimates for all-cause mortality and the cardiovas-
ular composite end point were determined accord-
ng to LV geometric patterns and were presented as
vent curves. All p values were 2-sided; p  0.05 was
sed to determine statistical significance. Statistical
nalyses were performed using STATA software,
ersion 8.2 (Stata Corp., College Station, Texas).
E S U L T S
aseline characteristics. The baseline LVMi and
WT for the 603 patients in the VALIANT
chocardiographic cohort were normally distrib-
ted. The mean LVMi (g/m2) was 98.8  28.4
range: 40.1 to 203.7) and the mean RWT was 0.38
0.08 (range: 0.19 to 0.70). In the VALIANT
chocardiographic cohort concentric hypertrophy
as present in 76 (12.6%) patients, eccentric hyper-
rophy in 112 (18.6%) patients, and concentric
emodeling was present in 110 (18.2%) patients at
aseline. Increased LVMi was associated with
igher rates of prior MI, history of hypertension,
iabetes mellitus, prior congestive heart failure, and
troke when compared with patients with normal
eometry. Moreover, patients with LV hypertrophy
ere older, more likely to be female, had lower
aseline estimated glomerular filtration rate, and
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585ower rates of primary percutaneous transluminal
oronary angioplasty (Table 1). No differences were
bserved among groups with regard to treatment
ith aspirin, calcium channel blocker, statins, and
eta-blockers.
The LV volumes were significantly increased and
Table 1. Baseline Characteristics Stratiﬁed by LV Geometric Pat
Characteristics
Normal Geometry
(n  305)
Con
Age, yrs 60.8 12.5
White, % 97
Female, % 23
Medical history, %
MI 26
Hypertension 47
Diabetes mellitus 16
HF 12
Stroke 3
Site of qualifying MI, %
Anterior 59
Inferior 35
Type of qualifying MI, %
Q-wave 69
Non–Q-wave 30
BMI, kg/m2 28.3 5.2
eGFR, ml/min/1.73 m2 75.6 20.2
Killip class I, % 69
Heart rate, beats/min 76.0 12.9
Blood pressure, mm Hg
Systolic 120.2 14.7
Diastolic 70.3 10.4
Medications at randomization, %
Beta-blocker 76
Aspirin 93
Calcium channel blocker 6
Statin 39
Study medications, %
Captopril 34
Valsartan 31
Captopril/valsartan 35
Thrombolytic therapy,† % 43
PTCA,† % 19
CABG,† % 2
Values are presented as mean  standard deviation, unless otherwise indicate
and before the patients were randomly assigned to a treatment group.
BMI  body mass index; CABG  coronary artery bypass graft; eGFR  estim
percutaneous transluminal coronary angioplasty.VEF and RV function were significantly reduced gn patients with eccentric hypertrophy (Table 2).
he LA volume index increased significantly with
ncreasing LV mass and was significantly higher in
atients with eccentric and concentric hypertrophy.
he LV mass to end-diastolic volume ratio and
verage LV wall thickness increased from normal
s
ric Remodeling
 110)
Eccentric Hypertrophy
(n  112)
Concentric Hyper
(n  76)
4.5 11.8 66.9 11.5* 70.2 9.8*
93 93 92
28 44 55
21 38 30
60 64 76
30 29 30
9 28 24
12 11 12
60 60 59
37 33 24
69 63 53
30 36 46
7.9 5.4 27.2 4.4 27.8 5.6
3.7 19.2 64.1 18.1* 61.7 21.1
78 77 80.3
5.0 11.4 76.0 12.2 75.0 11.8
0.2 13.7 121.1 15.0 125.5 16.4
0.3 10.4 71.9 11.6 69.6 12.0
76 69 67
90 93 92
7 12 4
38 27 38
34 33 34
35 38 33
31 29 33
44 29 29
30 5 12
2.7 1 0
 0.001 versus patients with normal LV geometry. †The procedure took place in
glomerular ﬁltration rate; HF  heart failure; LV  left ventricular; MI  myoctern
cent
(n
trophy
p Value
6 0.001
0.13
0.001
0.02
0.001
0.001
0.001
0.002
0.98
0.23
0.08
0.053
2 0.32
7 * 0.0001
0.07
7 0.84
12 0.047
7 0.49
0.22
0.81
0.15
0.11
0.86
0.01
0.001
0.45
d. *p the interval after the MI
ated ardial infarction; PTCA eometry to concentric hypertrophy. Infarct seg-
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586ent length was lower in patients with LV con-
entric remodeling and higher in patients with
ccentric hypertrophy. Patients with concentric re-
odeling had significantly lower LV end-systolic
olume and transmitral E/A ratio (E  peak early
iastolic velocity; A  peak late diastolic velocity).
here were no differences at baseline across the 4
roups with regard to deceleration time.
elationship between baseline LV mass, geometry, and
linical outcomes. Of the 603 patients in the VAL-
ANT echocardiographic cohort, 103 (17%) pa-
ients died, 162 (27%) experienced a composite of
eath or development of heart failure, and 187
31%) experienced composite cardiovascular out-
omes generated by adding important nonfatal
ardiovascular events (recurrent MI, hospitalization
or heart failure, resuscitation from cardiac arrest,
nd stroke) to death from cardiovascular causes
fter randomization. There were no significant
ifferences in the number of events by treatment
roup in this cohort (13). When analyzed as a
ontinuous variable, baseline LVMi was a potent
nivariate predictor of all-cause mortality (hazard
atio [HR]: 1.28; 95% confidence interval [CI]: 1.2
o 1.3), cardiovascular death (HR: 1.30; 95% CI:
ocardiographic Characteristics Stratiﬁed by LV Geometric Pattern
hic
cs
Normal Geometry
(n  305)
Concentric Remodeling
(n  110)
59.3 13.9 55.2 10.6
36.2 10.7 32.7 7.1†
39.5 5.5 40.8 4.7
0.35 0.04 0.48 0.05*
ess, cm 0.9 0.09 1.0 0.1*
168.1 39.2 166.3 35.4
84.2 16.9 85.5 14.8
1.5 0.3 1.6 0.3†
22.1 7.0 21.5 5.9
42.5 4.0 42.1 4.0
7.3 2.2 6.4 1.8†
1.4 0.7 1.1 0.6†
156.2 38.6 161.6 37.4
52.5 62
40 26.2
re 7.5 12
ean  standard deviation, unless otherwise indicated. *p  0.001 versus patients
h normal LV geometry.
locity; DT  deceleration time; E  peak early diastolic velocity; EDV  end-diast
dex; LV  left ventricular; LVEF  left ventricular ejection fraction; LVMi  left ve
ve wall thickness..2 to 1.36), death or heart failure hospitalization LHR: 1.30; 95% CI: 1.30 to 1.40), and cardiovas-
ular composite (HR: 1.28; 95% CI: 1.23 to 1.30),
ll p  0.001. In a multivariable adjusted model,
ach 10 g/m2 increase in LVMi and each 0.1 unit
ncrease in LV mass to end-diastolic volume ratio
ere independently associated with increased risk
or all-cause mortality, cardiovascular death, and
eath or heart failure hospitalization (each p 
.001) (Figs. 1A and 1B).
After adjusting for LV mass in addition to other
ovariates in the model, each 0.1 unit (10%) in-
rease in RWT was independently associated with
ncreased risk for the previously defined end points
each p  0.001) (Fig. 1C). Both concentric and
ccentric hypertrophy were significantly associated
ith increased risk of adverse outcome, with the
ighest mortality rates observed for patients with
oncentric hypertrophy (Figs. 2A, 2B, and 3).
here was a wide spectrum of risk across the
ategories of LV geometrical patterns, with early
ivergence of the Kaplan-Meier curves for the
omposite end point (Fig. 2B). In a multivariable
djusted model, patients with concentric remodel-
ng or with eccentric or concentric LV hypertrophy
ad worse outcomes than the patients with normal
centric Hypertrophy
(n  112)
Concentric Hypertrophy
(n  76) p Value
71.2 18.1* 62.6 15.0 0.001
45.0 14.1* 38.9 11.8 0.001
37.4 6.4† 38.3 6.0 0.001
0.35 0.05 0.48 0.05* 0.0001
1.0 0.1* 1.2 0.09* 0.0001
246.5 55.4* 246.3 54.5* 0.0001
129.1 23.4* 132.4 23.9* 0.0001
1.9 0.4* 2.2 0.5* 0.0001
29.5 9.7* 28.3 8.2* 0.0001
40.4 5.3‡ 41.5 3.9 0.001
8.1 2.9† 7.0 2.2 0.001
1.5 0.8 1.2 0.7 0.003
154.3 40.9 158.6 39.2 0.60
22.6 37.1
54.8 43.5 0.001
22.6 19.4
normal LV geometry. †p  0.05 versus patients with normal LV geometry. ‡p
volume; EDVi  end-diastolic volume index; ESVi  end-systolic volume index;
lar mass index; MR  mitral regurgitation; RVFAC  right ventricular fractionalTable 2. Baseline Ech s
Echocardiograp
Characteristi
Ec
EDVi, ml/m2
ESVi, ml/m2
LVEF, %
RWT
Average LV wall thickn
LV mass, g
LVMi, g/m2
LV mass/EDV
LAVi, ml/m2
RVFAC, %
Infarct length, cm
Doppler
E/A ratio
DT, ms
MR grade, %
No
Mild
Moderate or seve
Values are presented as m with
 0.01 versus patients wit
A  peak late diastolic ve olic
LAVi  left atrial volume in ntricu
area change; RWT  relatiV geometry. In particular, patients in the concen-
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587ric LV hypertrophy group had the highest rate of
atal and nonfatal events (Table 3).
I S C U S S I O N
n this high-risk cohort of patients with LV
ystolic dysfunction, heart failure, or both follow-
ng MI, echocardiographically determined LV
ass, RWT, and LV geometry are significant
ndependent predictors of increased cardiovascu-
ar morbidity and mortality. Concentric hyper-
rophy carried the greatest cardiovascular risk,
ollowed by eccentric hypertrophy, and then con-
entric remodeling. Our results confirm the im-
ortance of LV mass and geometry following MI
nd argue for their routine assessment in high-
isk patients with LV systolic dysfunction, heart
ailure, or both following MI.
Increased LV mass results from increased hemo-
ynamic load and is an independent predictor of
ubsequent cardiovascular morbidity and all-cause
ortality (1,2). Volume and pressure overloads, or a
ombination of both, cause different LV geometric
daptations including concentric ventricular remod-
ling, eccentric hypertrophy, and concentric hyper-
rophy. Geometric patterns identify distinctive
athophysiologic patterns and may be added to LV
ass for risk stratification (5–11). Even though
ardiovascular risk associated with LV mass is well
stablished in patients with hypertension, the prog-
ostic implication of LV geometry and RWT has
ot been clearly demonstrated in a high-risk
ost-MI population (16,17). Our analysis of the
ALIANT echocardiographic cohort provides
omprehensive information concerning significant
ardiovascular risk associated with LV mass and
WT in a population of high-risk post-MI indi-
iduals. An important finding of this study shows
hat concentric LV hypertrophy carries the highest
isk of adverse events, even after adjusting for
ell-established risk factors such as LVEF, hyper-
ension, and estimated glomerular filtration rate,
nd adds incremental prognostic value over the
ther known predictors of outcome. Several factors
ncluding hypertension and activation of the renin-
ngiotensin-aldosterone system induce LV hyper-
rophy and progression of atherosclerosis. Patho-
ogic increase in LV mass beyond the need to
ompensate for increased cardiac load is found
hen LV geometry is concentric (18,19) and is
ssociated with increased collagen deposition in the
xtracellular matrix and around the intramyocardial
oronary arteries with medial thickening of the0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5
Adjusted Hazard Ratios
Calculated for every 10 gm/m2 increase in baseline LVMi
Death/HF 1.26 (1.2-1.3)
CV Composite 1.22 (1.2-1.3)
CV Death 1.2 (1.1-1.3)
Death 1.19 (1.1-1.3)
A
0.8 0.9 1.0 1.1 1.2 1.3 1.4
Adjusted Hazard Ratios
Calculated for every 0.1 unit increase
in baseline LV mass/EDV ratio
Death/HF 1.1 (1.06-1.13)
CV Composite 1.08 (1.05-1.1)
CV Death 1.08 (1.04-1.13)
Death 1.09 (1.04-1.13)
B
0.80.6 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4
Adjusted Hazard Ratio
Calculated for every 0.1 unit increase in baseline RWT
Death/HF 1.8 (1.5-2.2)
CV Composite 1.6 (1.3-1.9)
CV Death 1.7 (1.3-2.2)
Death 1.7 (1.3-2.2)
C
Figure 1. Adjusted Hazard Ratios (95% Conﬁdence Intervals) for Adverse Outcomes
Multivariable Cox proportional hazards models were used to determine the independent
prognostic value of left ventricular mass index (LVMi), LV mass/end-diastolic volume
(EDV), and relative wall thickness (RWT). The models were adjusted for age (years), pri-
mary percutaneous transluminal coronary angioplasty, atrial ﬁbrillation complicating
myocardial infarction (MI), history of diabetes, history of hypertension, prior MI, Killip class,
history of congestive heart failure (HF), new left bundle branch block, history of angina, LV
ejection fraction, estimated glomerular ﬁltration rate, and a history of chronic obstructive
pulmonary disease. Each 10 g/m2 increase in LVMi (A), 0.1-U (10%) increase in LV mass to
end-diastolic volume ratio (B), and 0.1-U (10%) increase in RWT (C) were independently
associated with increased risk for death, cardiovascular (CV) death, and death or heart failure
hospitalization (each p  0.001). Echocardiographically determined LV mass and RWT are
signiﬁcant independent predictors of increased cardiovascular morbidity and mortality in
high-risk post-MI patients warranting their routine assessment.
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588ntramyocardial coronary arteries and disturbances
f myocardial blood flow (20,21). Although myo-
ardial afterload is the prime stimulus that pro-
otes the cascade of biological events leading to
entricular hypertrophy to reduce wall stress, con-
entric LV hypertrophy is eventually associated
ith increased cardiovascular risk (22). Left ven-
ricular hypertrophy secondary to hypertension, in-
arction, obesity, or valvular heart disease leads to
hifts toward glycolytic metabolism, disorganization
f the sarcomere, alterations in calcium handling,
hanges in contractility, loss of myocytes with
brotic replacement, systolic and diastolic dysfunc-
ion, and electrical remodeling resulting in alter-
tions in myocardial metabolism, structure, and
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Unadjusted Kaplan-Meier Curves Stratiﬁed by LV
ic Patterns
eier estimates for clinical outcomes for all-cause mortality (A) and
mposite end point (CV death, recurrent MI, heart failure, stroke,
citated sudden death) (B) were determined for LV geometric pat-
were presented as event curves. There was a wide spectrum of
s the categories of LV geometrical patterns, with early divergence
plan-Meier curves for mortality and composite end point, particu-
een patients with normal geometry and those with concentric
hy. Concentric hypertrophy carried the greatest CV risk, followed
ric hypertrophy, and then concentric remodeling, underscoring the
e of increased LV mass and RWT as important risk predictors fol-
gh risk MI. Abbreviations as in Figure 1.unction with increasing severity of LV hypertrophy e23). These structural, metabolic, and functional alter-
tions possibly associate LV hypertrophy with adverse
ardiovascular risk and heart failure development.
In addition, the present study demonstrates that
ncreasing baseline LV mass is also associated with
ncreasing incidence of resuscitated sudden death.
eft ventricular hypertrophy has long been known
o be associated with sudden cardiac death and
ncreased risk of ventricular arrhythmias (24–26),
nd it may be related to prolongation of action
otential, increased dispersion of refractoriness, and
owering of the ventricular fibrillation threshold
24). Of note, we also observed increasing incidence
f stroke associated with abnormal LV geometry,
oth concentric hypertrophy and concentric remod-
ling were associated with an increased risk of
troke. Left ventricular hypertrophy has long been
ssociated with risk of ischemic stroke (27–29).
ecently, Di Tullio et al. (30) reported association
f abnormal LV geometry and RWT with stroke
isk in a population-based case control study. Our
tudy extends those findings to a high-risk post-MI
opulation.
It is also noteworthy that despite being associated
ith similar left and right systolic function, concen-
ric LV remodeling was also associated with poor
rognosis compared with patients with normal LV
eometry in this high-risk post-MI population. In
ur observations, concentric remodeling was asso-
iated with a 3-fold increase in fatal and nonfatal
ardiovascular events following a high-risk MI. The
ssociation of concentric remodeling with increased
isk is supported by Verdecchia et al. (11), who
emonstrated that in the presence of normal LV
ass, concentric LV remodeling reflecting a nearly
ure pressure overload was associated with worse
utcome. These observations suggest that both
hamber dilation in the form of eccentric hypertro-
hy and increased RWT in the form of concentric
V hypertrophy and concentric remodeling are
ndependently related to adverse cardiovascular
vents.
tudy limitations. Although our findings are
trengthened by involving a larger cohort of ran-
omized subjects receiving contemporary post-MI
herapy and the nearly complete follow-up associ-
ted with this trial, some limitations should be
oted. First, 2-dimensional echocardiography is
imited in its accuracy for measuring LV mass
ecause all methods assume a uniform LV thick-
ess, which is not the case in areas of chronic MI or
ith geometric deformity of the LV cavity. How-A
Cu
m
ul
at
iv
e 
In
ci
de
nc
e
Cu
m
ul
at
iv
e 
In
ci
de
nc
e
0
0
1
0
0
0
B
Figure 2.
Geometr
Kaplan-M
the CV co
and resus
terns and
risk acros
of the Ka
larly betw
hypertrop
by eccent
importancver, the M-mode methods based on the simple
c
t
i
s
p
e
i
t
m
l
m
e
c
m
d
l
t
t
b
t
m
r
e
g
p
e
S
p
t
F
t
g
p
C
E
g
p
f
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 , N O . 5 , 2 0 0 8
S E P T E M B E R 2 0 0 8 : 5 8 2 – 9 1
Verma et al.
Prognostic Implication: LV Mass and Geometry Post-MI
589ube-function formula have repeatedly been shown
o give reasonably accurate LV mass measurements
n necropsy validation studies. In addition, the
implicity and ease of this technique has made it
ossible for application to large-scale clinical and
pidemiological studies and to relate LV mass and
ts change over time to clinical outcomes (31). On
he other hand, the 2-dimensional methods for
easuring LV mass that are based on the area-
ength formula and the truncated ellipsoid model
ight be more accurate, but because this is also
xpertise-dependent and time-consuming, its appli-
ability is limited to a large-scale study. None of the
ethods described to measure LV mass are vali-
ated in the post-MI setting. However, despite its
imitations, we do not expect the degree of wall
hickness to change abruptly after an acute MI and
he method used in this study was applied in a
linded fashion to a large sample of patients;
herefore, the association between increased LV
ass, abnormal LV geometry, and cardiovascular
isk is likely to be real. In addition, first, baseline
chocardiograms in the VALIANT echocardio-
raphic study were obtained during the early
ost-MI period, thus precluding any significant LV
nlargement and were devoid of any LV aneurysm.
econd, we did not assess for serial changes in blood
ressure and in LV mass and its geometrical pat-
erns and potential influence on cardiovascular risk.
inally, our results are predominantly applicable to
he high-risk cohort of VALIANT, which limits
eneralization to the broader group of post-MI
atients.
Table 3. HR (Chi-Square: 95% CI) Stratiﬁed by LV Geometric Pa
Outcome
Normal
Geometry
Concentr
Remodelin
Death
Unadjusted HR Ref 2.7 (7.1: 1.4–5
Adjusted HR‡ Ref 3.5 (10.7: 1.6–
CV death
Unadjusted HR Ref 2.6 (7.9: 1.3–5
Adjusted HR‡ Ref 3.4 (8.9: 1.5–7
Death or HF
Unadjusted HR Ref 2.9 (16.1: 1.7–
Adjusted HR‡ Ref 4.2 (21.4: 2.1–
CV composite
Unadjusted HR Ref 2.4 (14.1: 1.5–
Adjusted HR‡ Ref 3.0 (19.9: 1.9–
Values presented as hazard ratio (HR) (chi-square: 95% conﬁdence interval [CI]).
complicating MI, history of diabetes, history of hypertension, prior MI, Killip cla
LVEDV, infarct length, LAVi, eGFR, and a history of chronic obstructive pulmon
CV  cardiovascular death; LVEDV  left ventricular end-diastolic volume; Ref  rO N C L U S I O N S
chocardiographically determined LV mass and its
eometrical patterns are important independent
redictors of increased morbidity and mortality
ollowing high-risk MI. Concentric LV hypertro-
In
ci
de
nc
e 
Ra
te
/1
00
 p
er
so
n-
ye
ar
s
CV
Death
10
* p<0.001
†
 p<0.01
20
30
40
50
60
70
80
90
100
0
Reinfarction HF Stroke SD
Co
Normal Concentric
remodeling
Eccentric
hypertrophy
Conce
hypert
Figure 3. Crude Incidence Rates per 100-Person Years
Crude incidence rates per 100 person-years were calculated for the
time-dependent clinical CV outcomes and depicted as bar graph, fo
geometrical patterns. Concentric hypertrophy carried the greatest in
rate for adverse CV outcomes including CV mortality, recurrent MI,
failure, stroke and sudden cardiac death. Even concentric remodelin
associated with poor prognosis compared with patients with norma
geometry. Concentric hypertrophy had higher incidence rates for C
ity and heart failure development and also recurrent MI, stroke, and
cardiac death. Routine echocardiographic assessment of LV mass an
geometry following a high-risk MI is important. SD  sudden death
abbreviations as in Figure 1.
s Group
Eccentric
Hypertrophy
Concentric
Hypertrophy
5.0 (32.1: 2.9–8.8)† 8.0 (4.6–13.9)†
3.4 (7.5: 1.3–5.1)* 6.1 (26.7: 3.1–12.1)†
5.0 (28.8: 2.8–9.0)† 7.9 (48.3: 4.4–14.3)†
2.6 (6.4: 1.2–5.3)* 6.5 (28.8: 3.1–13.6)†
6.3 (61.8: 4.0–9.9)† 11.7 (113.0: 7.4–18.5)†
3.5 (19.6: 2.6–7.0)† 8.9 (68.5: 5.4–14.9)†
4.5 (52.2: 3.0–6.7)† 7.7 (96.4: 5.1–11.6)†
3.1 (12.0: 1.9–4.8)* 5.4 (51.7: 3.4–8.5)†
0.01. †p  0.001. ‡Adjusted for age (in years), primary PTCA, atrial ﬁbrillation
istory of congestive HF, new left bundle branch block, history of angina, LVEF,
isease.CV
mposite
ntric
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deﬁned
r LV
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heart
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sudden
d its
; otherttern
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.0)*
7.3)*
.1)*
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ss, h
ary deferent value; other abbreviations as in Tables 1 and 2.
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590hy carries the greatest risk of adverse cardiovascu-
ar events including death. Even the presence of
oncentric geometry in the absence of increased LV
ass is associated with an increased risk of subse-
uent cardiovascular complications, underscoring
he importance of increased baseline LV mass and
WT as important risk predictors in patients fol-
owing high-risk MI. Our findings demonstrate
hat routine assessment of LV mass and RWT cancated essential hypertension. Ann In-
tern Med 1991;114:345–52. pertrophy in non–Qigh-risk MI with LV systolic dysfunction, heart
ailure, or both, and raise the question of whether
pecific therapies can be developed to improve
rognosis in these high-risk patients.
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